2022 - Sanofi | Paediatric HIV

top of page

HIV TREATMENT

2020

Pharmaceutical companies, SRAs, WHO Prequalification Programme (PQ) and NRAs commit to:

Action 27. Mobilize their networks and work with communities to help build treatment literacy, generate demand, and expand access to ARVs among children.

Action 34. Increase efforts to share information on the roll-out of new paediatric formulations, including lessons learned.

Paediatric HIV & TB : Rome Action Plan

Previous Committements

2022 Rome Action Plan on Paediatric HIV & TB

Sanofi

HIV MEDICINES DURING PREGNANCY AND BREASTFEEDING

Sanofi commits to:

406. Continue to support research networks conducting studies to confirm rifapentine dosing in young children, including children living with HIV, guaranteeing supply and availability of the product.

Updates

bottom of page